From USD 0.98 billion in 2022, The Global Flu Treatment Market is Predicted to Grow to USD 1.8 billion by 2030, Registering a CAGR Of 5.3% During the Forecast Period (2023–2030)
From USD 0.98 billion in 2022, the global flu treatment market is predicted to grow to USD 1.8 billion by 2030, registering a CAGR of 5.3% during the forecast period (2023–2030). An excessive innovation undertaken by the key manufacturers of drug is the key trends observed in the growth of global flu treatment market. Rapid innovations and research assignments are being massively undertaken in order to combat COVID-19 situation globally. This innovation is out most important in the situation where coronavirus is at peak globally and is further expected to prevail for which vital treatments is to be implemented as soon as possible as human life is endangered in the present scenario. As a result, to this innovation in drugs global flu treatment market is expected to witness positive growth.
The hospital pharmacy segment is expected to witness highest CAGR during the forecast period in the global flu treatment market
On the basis of distribution channel, the global flu treatment market is classified into hospital pharmacy, retail pharmacy, and others. Amongst these segments, hospital pharmacy is expected to witness highest CAGR during the forecast period as the large numbers of patients across the globe are suffering from COVID-19 crisis that is further accentuating the global flu treatment market.
Global Flu Treatment Market Segmentation Analysis
|
Segment |
Categorization |
Leading Category |
|
Type |
Type A, Type B, Type C |
Type A (Largest)
|
|
Route of Administration |
Oral, Parenteral, Others |
Parenteral (Fastest) |
|
Medication |
Analgesics, Antiviral Drugs, Antihistamines, Others |
Antiviral Drugs (Largest)
|
|
End User |
Hospitals, Specialty Clinics, Others |
Hospitals (Largest and Fastest) |
|
Distribution Channel |
Hospital Pharmacy, Retail Pharmacy, Others |
Hospital Pharmacy (Fastest) |
|
Region |
North America, Europe, Asia-Pacific, and Rest of the World |
Europe (Largest) Asia-Pacific (Fastest) |
Discover more about this report, Download Free Sample Copy of Flu Treatment Market
Geography Insight
Geographically, Europe was the largest flu treatment market in 2022. This is owing to the massive oubreak of COVID-19 in the region. According to a report published by European Union, approximately 1,563,857 cases of COVID-19 has been discovered in Europe till first week of April and total deaths registered in the region were 95,044. As a result to this the demand for developing vaccines is out most important in order to reduce the death counts and those affected by the virus.
The Asia-Pacific flu treatment market is projected to witness fastest growth in the global flu treatment market during the forecast period, owing to the outbreak of COVID-19 in countries such as India that has recently exploded in the country, and also in China where the origin of COVID-19 patients occurred.
Competitive Insight
Some of the key players operating in the global flu treatment market are GlaxoSmithKline plc, AstraZeneca, Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, Novartis AG, NATCO Pharma Limited, Merck & Co., F. Hoffmann-La Roche Ltd, Inc., Bayer AG, Mylan N.V., Pfizer Inc., and Sanofi.
Scope of the Report
|
Report Metric |
Details |
|
Market Size Available for the Years in the Study |
2018 – 2030 |
|
Historical Period |
2018 – 2022 |
|
Base Year |
2022 |
|
Forecast Period |
2023 – 2030 |
|
Segments Covered in the Study |
Type, Route of Administration, Medication, End User, Distribution Channel, and Region |
|
Geographies Covered in the Study |
North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Spain, Russia), Asia-Pacific (China, Japan, India, Australia, Singapore, South Korea, Indonesia), and Rest of the World (Brazil, Argentina, South Africa, Saudi Arabia, Iran, U.A.E.) |
|
Companies Covered in the Study |
GlaxoSmithKline plc, AstraZeneca, Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, Novartis AG, NATCO Pharma Limited, Merck & Co., F. Hoffmann-La Roche Ltd, Inc., Bayer AG, Mylan N.V., Pfizer Inc., and Sanofi |
Global Flu Treatment Market Coverage
Type Insight and Forecast 2018 – 2030
- Type A
- Type B
- Type C
Route of Administration Insight and Forecast 2018 – 2030
- Oral
- Parenteral
- Others
Medication Insight and Forecast 2018 – 2030
- Analgesics
- Antiviral Drugs
- Antihistamines
- Others
End User Insight and Forecast 2018 – 2030
- Hospitals
- Specialty Clinics
- Others
Distribution Channel Insight and Forecast 2018 – 2030
- Hospital Pharmacy
- Retail Pharmacy
- Others
Geographical Segmentation
Flu Treatment Market by Region
North America
- By Type
- By Route of Administration
- By Medication
- By End User
- By Distribution Channel
- By Country – U.S., Canada, and Mexico
Europe
- By Type
- By Route of Administration
- By Medication
- By End User
- By Distribution Channel
- By Country – Germany, U.K., France, Italy, Spain, Russia, and Rest of Europe
Asia-Pacific (APAC)
- By Type
- By Route of Administration
- By Medication
- By End User
- By Distribution Channel
- By Country – China, Japan, India, Australia, Singapore, South Korea, Indonesia, and Rest of Asia-Pacific
Rest of the World (RoW)
- By Type
- By Route of Administration
- By Medication
- By End User
- By Distribution Channel
- By Country – Brazil, Argentina, South Africa, Saudi Arabia, Iran, U.A.E., and Other Countries
Benefits of Report Purchase from VynZ:
We provide accurate data and in-depth analysis with all-inclusive coverage. We focus on robust research methodology and data triangulation to ensure high quality report. We believe in providing 24*7 analyst support to our client – Pre and post purchase of the report as well as during the project tenure.
We also offer 20% post purchase free customization in the study to meet your needs. Due. We claim full customer satisfaction as our core values lie in building long term relationships.